Technical Analysis for MRTX - Mirati Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 194.89 -1.88% -3.73
MRTX closed down 1.88 percent on Monday, October 19, 2020, on 78 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 2
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical MRTX trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -1.88%
New 52 Week High Strength -1.88%
Upper Bollinger Band Walk Strength -1.88%
Older End-of-Day Gignals for MRTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 5 hours ago
Outside Day about 5 hours ago
Fell Below Previous Day's Low about 5 hours ago
Down 2 % about 6 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Medicine Biopharmaceutical Cancer Solid Tumors Chemical Compounds Oncology Lymphoma Non Small Cell Lung Cancer Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib

Is MRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 203.77
52 Week Low 66.01
Average Volume 424,583
200-Day Moving Average 112.88
50-Day Moving Average 157.39
20-Day Moving Average 176.50
10-Day Moving Average 187.90
Average True Range 8.24
ADX 44.19
+DI 33.52
-DI 9.69
Chandelier Exit (Long, 3 ATRs ) 179.05
Chandelier Exit (Short, 3 ATRs ) 179.44
Upper Bollinger Band 202.07
Lower Bollinger Band 150.93
Percent B (%b) 0.86
BandWidth 28.98
MACD Line 11.70
MACD Signal Line 10.27
MACD Histogram 1.4388
Fundamentals Value
Market Cap 8.68 Billion
Num Shares 44.5 Million
EPS -4.19
Price-to-Earnings (P/E) Ratio -46.57
Price-to-Sales 4288.10
Price-to-Book 13.60
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 211.72
Resistance 3 (R3) 212.81 208.29 208.92
Resistance 2 (R2) 208.29 204.00 207.75 207.98
Resistance 1 (R1) 201.59 201.36 199.33 200.50 207.04
Pivot Point 197.07 197.07 195.94 196.53 197.07
Support 1 (S1) 190.37 192.78 188.11 189.28 182.74
Support 2 (S2) 185.85 190.14 185.31 181.80
Support 3 (S3) 179.15 185.85 180.87
Support 4 (S4) 178.06